Kimberly-Clark enters the week before its July 21 earnings with an unusual tension: options traders are the most bullishly positioned they've been in a year, yet short interest remains structurally elevated — a divergence that makes this a more charged setup than the stock's sleepy consumer-staples reputation might suggest.
The options market is sending its clearest bullish signal in twelve months. The put/call ratio dropped to 0.46 on June 16 — more than two standard deviations below its 20-day average of 0.54, and the lowest reading recorded in the past year. That's a decisive shift toward call-side demand. The move coincides with a strong month for the stock: KMB is up 8.7% over the past month and 3.7% on the week, closing at $104.28. Options traders appear to be reaching for upside rather than hedging against further losses.
Short interest tells a less comfortable story. Bears remain firmly entrenched, with 13.5% of the free float currently sold short — a level that qualifies as genuinely elevated for a household-products company. Short positions grew roughly 5.4% over the past month, though they edged back fractionally on the latest day. The borrow market, however, gives shorts no reason to panic: cost to borrow is a negligible 0.55%, and availability is running at 185% — meaning nearly twice as many shares remain available to lend as are currently borrowed. The ORTEX short score has been grinding higher, reaching 73 this week, its highest level in the 10-day window shown. That places the stock in the 7th percentile on short-score rank — elevated bearish positioning, but no borrow squeeze in sight.
The Street is cautiously optimistic, with a clear split between bulls and fence-sitters. Piper Sandler raised its price target to $121 from $115 just this week, maintaining an Overweight rating — the most recent and directionally constructive move in the analyst file. BofA holds a Buy with a $120 target. Against that, UBS sits at Neutral ($106), Barclays at Equal-Weight ($99), and Wells Fargo at Equal-Weight ($100). The consensus mean target of roughly $114.67 implies about 10% upside from current levels — respectable, but not a ringing endorsement when the stock is already up nearly 9% in a month. The bull case rests on brand strength across Huggies, Kleenex, and Depend, plus potential synergies from the Kenvue consumer health acquisition feeding through by 2028. Bears point to weakening North American retail scan data — a -2.8% February decline — and EPS estimates that have been trimmed over recent months.
Institutional ownership is dominated by passive index holders. BlackRock, State Street, and two Vanguard entities together account for roughly 27% of shares. Two Sigma added over 3 million shares as of March 31 — a meaningful position build from a quantitative manager — while Wellington added 1.6 million. Neither signals a thesis-driven catalyst, but the presence of active and quant money alongside the index base means the float is not entirely inert. Insider activity from early May showed routine post-award sells by the CEO, CFO, and controller — all at prices in the high-$90s, well below the current level — carrying low significance scores and no net buying signal.
With Q2 results due July 21, the key variable is whether North American organic sales can stabilise after the Q1 softness. Past earnings prints have been muted but negative on the day — down roughly 1.2% and 2.2% at the two most recent releases — though the five-day drift turned positive after the May report. The contrast between call-heavy options positioning and persistently high short interest is the setup to watch heading into that print.
See the live data behind this article on ORTEX.
Open KMB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
